<DOC>
	<DOCNO>NCT00528723</DOCNO>
	<brief_summary>The purpose trial verify test treatment BDP 250 mcg/salbutamol 100 mcg HFA pMDI fix combination non-inferior BDP 250 mcg/salbutamol 100 mcg pMDI fix combination give conventional CFC propellant ( Clenil® Compositum 250 , Chiesi Farmaceutici ) term Pulmonary Function ( morning PEF ) .</brief_summary>
	<brief_title>Efficacy Tolerability Beclomethasone Plus Salbutamol HFA pMDI Fixed Combination v Beclomethasone Plus Salbutamol CFC pMDI Fixed Combination 12-week Treatment Period Adult Patients With Uncontrolled Asthma</brief_title>
	<detailed_description>Asthma chronic inflammatory disorder airways serious public health worldwide problem , affect people age , estimate 300 million affect individuals.When uncontrolled , asthma place severe limit daily life , sometimes fatal . There two major class inhale therapy treatment reversible obstructive airway disease : antinflammatory agent bronchodilator . In particular , BDP 250 mcg plus salbutamol 100 mcg fix combination effective safe method control symptoms persistent asthma adult . This study design compare efficacy , safety tolerability new BDP 250 mcg/salbutamol 100 mcg HFA pMDI fix combination CFC-formulated fixed combination , market decades.The HFA propel product develop replace CFC formulation already market accord European Union 's Committee Proprietary Medicinal Products ( CPMP ) Note Guidance ( III/5378/93 - Final ) order prevent depletion stratospheric ozone . The primary objective trial demonstrate test treatment BDP 250 mcg/salbutamol 100 mcg HFA pMDI fix combination non-inferior BDP 250 mcg/salbutamol 100 mcg pMDI fix combination give conventional CFC propellant ( Clenil® Compositum 250 , Chiesi Farmaceutici ) term Pulmonary Function ( morning PEF ) . Given aim study , population monitor include adult patient persistent asthma accord current guideline . The treatment period precede 2-week run-in period . Subjects satisfy inclusion exclusion criterion enter 12-week treatment period . Clinic visit take place start end run-in period , 2 , 4 , 8 12 week randomisation .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>1 . Written inform consent obtain , 2 . Male female outpatient age ³ 18 &lt; 65 year ; 3 . Uncontrolled asthma define accord GINA 2006 `` Classification Levels Asthma Control '' . This definition include presence two follow feature ( addition require range FEV1 ) : ) daytime asthma symptom &gt; twice week ; b ) limitation activity ; c ) nocturnal symptoms/awakening ; b ) need reliever/rescue treatment &gt; twice week . These condition base recent medical history confirm 2week runin period ; 4 . Forced expiratory volume first second ( FEV1 ) ³ 60 % &lt; 80 % predict normal value ; 5 . Positive response reversibility test screen visit , defined increase least 12 % ( , alternatively , 200 mL ) prebronchodilator value measurement FEV1 30 minute follow 4 puff ( 4 ´ 100 µg ) inhale salbutamol administer via pMDI . The reversibility test avoid patient document positive response previous 6 month ; 6 . Nonsmokers exsmokers cumulative tobacco exposure le 5 packyears stop smoke since 1 year ; 7 . A cooperative attitude ability train correctly use pMDIs ; 8 . At end 2week runin period , condition uncontrolled asthma ( see inclusion criterion No . 3 ) confirm review diary card runin . 1 . Inability carry pulmonary function test ; 2 . Diagnosis Chronic Obstructive Pulmonary Disease ( COPD ; 3 . History near fatal asthma ; 4 . Evidence severe asthma exacerbation symptomatic infection airways previous 4 week ; 5 . Three course oral corticosteroid hospitalisation due asthma previous 6 month ; 6 . Patients treat inhaled corticosteroid previous 4 week ; 7 . Patients treat nebulized , oral , intravenous intramuscular corticosteroid past 8 week depot injectable corticosteroid past 12 week ; 8 . Patients treat longacting β2agonist ( LABA ) past 2 week ; 9 . Patients treat oral β2agonist past 48 hour ; 10 . Patients treat shortacting β2agonist ( SABA ) past 6 hour ; 11 . Patients treat nebulized bronchodilator past 2 week ; 12 . Patients treat anticholinergic medication ( route ) past 2 week ; 13 . Patients treat xanthine derivative ( route ) past 4 week ; 14 . Patients treat inhaled cromone leukotriene modifier past 4 week ; 15 . History current evidence heart failure , coronary artery disease , myocardial infarction , severe hypertension , cardiac arrhythmia ; 16 . Diabetes mellitus ; 17 . Percutaneous transluminal coronary angioplasty ( PTCA ) coronary artery bypass graft ( CABG ) previous six month ; 18 . Patients abnormal QTc interval value ECG test , define &gt; 450 msec male &gt; 470 msec female ; 19 . Patients serum potassium value ≤ 3.5 mEq/L ( 3.5 mmol/L ) and/or fast serum glucose value ≥ 140 mg/dL ( 7.77 mmol/L ) ; 20 . Other haemodynamic relevant rhythm disturbance ( include atrial flutter atrial fibrillation ventricular response , bradycardia ( ≤ 55 bpm ) , evidence atrialventricular ( AV ) block ECG 1st degree ; 21 . Clinically significant unstable concurrent disease : uncontrolled hyperthyroidism , significant hepatic impairment , poorly control pulmonary ( tuberculosis , active mycotic infection lung ) , gastrointestinal ( e.g . active peptic ulcer ) , neurological haematological autoimmune disease ; 22 . Cancer chronic disease prognosis &lt; 2 year ; 23 . Pregnant lactating female female risk pregnancy , i.e . demonstrate adequate contraception ( i.e . barrier method , intrauterine device , hormonal treatment sterilization ) . 24 . History alcohol drug abuse ; 25 . Patients treat monoamine oxidase inhibitor , tricyclic antidepressant betablockers regular use ; 26 . Allergy , sensitivity intolerance study drug and/or study drug formulation ingredient ; 27 . Patients unlikely comply protocol unable understand nature , scope possible consequence study ; 28 . Patients receive investigational new drug within last 12 week ; 29 . Patients previously enrol study ; 30 . At end runin period , patient admit treatment period case increase FEV1 measure clinic end runin period ³ 15 % respect prebronchodilator value measure start runin period ; 31 . Patients asthma exacerbation runin period also exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>beclomethasone</keyword>
	<keyword>need</keyword>
	<keyword>salbutamol</keyword>
	<keyword>wheeze</keyword>
</DOC>